Allocated to IV arm (n=85) Allocated to HIA arm (n=86) Started allocated intervention (n=83) Did not receive allocated therapy (n=2) - Refusal (n=2) Started.

Slides:

Advertisements

Similar presentations

Figure 1. Number of Tuberculosis Cases: California, California Department of Public Health, Tuberculosis Control Branch Number of Tuberculosis.

Advertisements

Short introduction An example of the use of survival analysis.

Cardiovascular outcome in patients with dysglycemia with daily supplementation of n-3 fatty acids 1 ORIGIN trial (Outcome Reduction with an Initial Glargine.

Analysis & Expressing Resultd in Clinical Trials Dr. Khalili.

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results from All Randomized Patients.

Treatment Switching in the VenUS IV trial Methods to manage treatment non-compliance in RCTs with time-to-event outcomes Caroline Fairhurst York Trials.

Steffen Desch Thomas Okon, Diana Heinemann, Konrad Kulle, Karoline Röhnert, Melanie Sonnabend, Martin Petzold, Ulrike Müller, Gerhard Schuler, Ingo Eitel,

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Ablation for Paroxysmal Atrial Fibrillation (APAF) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Carlo.

Figure 1. Number of Tuberculosis Cases: California, California Department of Public Health, Tuberculosis Control Branch Number of Tuberculosis.

1 Efficacy Results NDA (MTP-PE) Laura Lu Statistical Reviewer Office of Biostatistics FDA/CDER.

Eastern cooperative oncology group E1496: ECOG and CALGB Cyclophosphamide/Fludarabine (CF) with or without Maintenance Rituximab (MR) in Advanced Indolent.

CS-1 Results of the Phase 3 Clinical Trials of Abraxane vs. Taxol in Metastatic Breast Cancer William J. Gradishar, MD, FACP Professor of Medicine Northwestern.

Comparison of Nilotinib and Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd Beyond One Year Larson.

Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study.

EVIDENCE BASED MEDICINE Effectiveness of therapy Ross Lawrenson.

Prevention of Recurrent Venous Thromboembolism N Engl J Med Apr ;348(15) : PREVENT (Warfarin) Trial.

Capecitabine versus Bolus 5-FU/Leucovorin as Adjuvant Therapy for Colon Cancer: X-ACT Trial Results James Cassidy, MD Colorectal Cancer Update Think Tank.

2,500 3,000 3,500 4,000 4,500 5,000 5,500 6,000 2,500 3,000 3,500 4,000 4,500 5,000 5,500 6,000 Figure 1. Number of Tuberculosis Cases: California,

Involved Field Radiotherapy versus No Further Treatment in Patients with Clinical Stages IA/IIA Hodgkin Lymphoma and a “Negative” PET Scan After 3 Cycles.

Figure. S1 Week Percent of VO 2peak Repeat CPET.

ITT populations EASTERN: n=216 WESTERN: n=234 Randomized to asenapine and received  1 treatment EASTERN: n=241 WESTERN: n=244 Randomized to olanzapine.

Phase II in Second Line NSCLC DefinitionPhase II: BI 6727 vs. BI 6727+pemetrexed vs. pemetrexed in second line advanced NSCLC Early stopping.

11 One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor A Randomized Trial Joensuu H, Eriksson M, Sundby Hall K, et al.

The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.

The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.

Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.

Ruan J et al. Proc ASH 2013;Abstract 247.

Number of Tuberculosis Cases: California, Number of Tuberculosis Cases.

Background: Ritonavir-boosted protease-inhibitor (PI)-monotherapies are an attractive alternative to conventional therapy in order to avoid the potential.

CALYPSO Trial: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum- Sensitive Ovarian Cancer Pujade-Lauraine.

Figure 1. Number of Tuberculosis Cases: California, Number of Tuberculosis Cases

بسم الله الرحمن الرحیم.

T T H H I I Tennessee Health Indicators PROGRAM DIRECTOR: DR. JON WARKENTIN DATA DIRECTOR/EPIDEMIOLOGIST: JASON CUMMINS, MPH Tuberculosis Elimination Program.

Disclosure Statement of Financial Interest

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Control of Sympathetic Drive With Continuous.

From: PLOS Neglected Tropical DiseaseJanuary 2014 Presented by Pavitra Charoensrisakkul and Peeraya Permkarnjaroen 3 rd year medical cadet Phramongkutklao.

Date of download: 6/2/2016 From: Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis.

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.

Date of download: 6/9/2016 From: Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus– Infected Patients Without.

Five Year Update of Cardiac Dysfunction in NSABP B-31 A Randomized Trial of AC  Paclitaxel vs. AC  Paclitaxel with Trastuzumab.

Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Adapalene Gel, 0.1%, as Maintenance Therapy for Acne.

Date of download: 7/7/2016 Copyright © The American College of Cardiology. All rights reserved. From: Heparin-Bonded Covered Stents Versus Bare-Metal Stents.

1 Statistical Issues in NDA Laura Lu, Ph.D FDA/CDER.

Date of download: 9/17/2016 From: Topical Treatment of Pressure Ulcers with Nerve Growth Factor: A Randomized Clinical Trial Ann Intern Med. 2003;139(8):

Sample Journal Club Your Name Here.

Figure 1. Flow diagram indicating progress of subjects through the study and stage at which subjects were lost to follow-up. A=mid-range mobilization,

A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis

Assessed for eligibility (n = 38)

Assessed for eligibility (N = )

Her2-positive breast cancer: updating current best practice

Avanafil for the Treatment of Erectile Dysfunction: A Multicenter, Randomized, Double- Blind Study in Men With Diabetes Mellitus Irwin Goldstein, MD,

مدیریت استراتژيک منابع انسانی

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 5 Examples of biomarker-guided trials

Maintenance therapy for cryptococcosis in patients with AIDS after successful primary therapy: oral fluconazole (300 mg daily) versus oral itraconazole.

The Road to Quality Improvement in HER2-Positive Breast Cancer

Need for better diabetes treatment for improved renal outcome

Randomized, controlled, open-label, non-inferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa F. Olivennes, G. Trew,

CoPrincipal Investigators

Ռազմավարական կառավարում

J. Garau Clinical Microbiology and Infection

Supplementary Figure 2A

Trial profile Luc F Van Gaal, Lancet 2005;365:1389.

Figure 2. Kaplan–Meier curves derived from data generated under study-specific assumptions. (A) Kaplan–Meier curves ... Figure 2. Kaplan–Meier curves derived.

A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma Alexander.

Assessed for eligibility N = 15593

379 failed screeninga 120 failed run inb

--- 6-months’ therapy months’ therapy Supplementary Figure 1.

Presentation transcript:

Allocated to IV arm (n=85) Allocated to HIA arm (n=86) Started allocated intervention (n=83) Did not receive allocated therapy (n=2) - Refusal (n=2) Started allocated intervention (n=66) Did not receive allocated therapy (n=20) - Refusal (n=2) - progressive disease (n=3) - Catheter placement (n=13) - Other (n=2) Lost to follow-up (n=2) Discontinued intervention (n=66) - Progression (n=37) - Toxicity (n=14) - Catheter dysfunction (n=11) - Refusal (n=1) - Other (n=3) Lost to follow-up (n=3) Discontinued intervention (n=83) - Progression (n=59) - Toxicity (n=22) - Catheter dysfunction (not applicable) - Refusal (n=1) - Other (n=1) Randomized (n=171) Ineligible (n=3) Excluded (n=0) ITT population (n=85) Per-protocol treatment population (n=83) ITT population (n=86) Per-protocol treatment population (n=66) Allocation Follow-up Analysis FIGURE S1

Logrank test: P=0.03 % patients alive FIGURE S2

Logrank test: P< % patients alive < UNL UNL - < 2xUNL > 2xUNL FIGURE S3